Benitec Biopharma
BNTC
72 hedge funds and large institutions have $427M invested in Benitec Biopharma in 2025 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 14 reducing their positions, and 4 closing their positions.
400% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 14
31% more capital invested
Capital invested by funds: $325M → $427M (+$102M)
29% more funds holding
Funds holding: 56 → 72 (+16)
5.29% more ownership
Funds ownership: 88.21% → 93.5% (+5.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$25.6M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$23.1M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$10.7M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$10.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$5.43M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$1.09M |
| 3 |
Goldman Sachs
New York
|
-$281K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$61.6K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$61.4K |
BNTC Hedge Fund Activity: Q4 2025 in Review
72 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2025, worth a combined $427M — up 31% from $325M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new BNTC positions and 4 closed out — a net gain of 16 holders — while 28 added to existing stakes and 14 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $25.6M. The largest seller was Franklin Resources, cutting an estimated $5.43M.
- 72 institutional investors held Benitec Biopharma (BNTC) as of Q4 2025, up from 56 in Q3 2025.
- Funds reported $427M of Benitec Biopharma stock for Q4 2025, up 31% quarter-over-quarter.
- 20 funds opened new Benitec Biopharma positions in Q4 2025 and 4 closed out, a net change of +16 holders.
- The largest Benitec Biopharma buyer in Q4 2025 was RA Capital Management, an estimated $25.6M added.
- The largest Benitec Biopharma seller in Q4 2025 was Franklin Resources, an estimated $5.43M sold.
Based on aggregated 13F filings for Q4 2025.